Fidelity Investments
TRIL

Fidelity Investments’s Trillium Therapeutics Inc. TRIL Stock Holding History

Fidelity Investments’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-84,760
Closed -$822K – 5340
2021
Q2 		$822K Sell
84,760
-88,700
-51% -$835K ﹤0.01% 2703
2021
Q1 		$1.86M Buy
173,460
+129,060
+291% +$1.6M ﹤0.01% 2483
2020
Q4 		$653K Buy
44,400
+6,000
+16% +$86.5K ﹤0.01% 2604
2020
Q3 		$546K Buy
+38,400
New +$383K ﹤0.01% 2523
2015
Q4 		– Sell
-93,875
Closed -$1.22M – 2793
2015
Q3 		$1.22M Buy
93,875
+13,923
+17% +$256K ﹤0.01% 2494
2015
Q2 		$1.73M Buy
+79,952
New +$1.82M ﹤0.01% 2468

Other funds holding TRIL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Fidelity Investments's TRIL Position: Q3 2021 in Review

Fidelity Investments sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2021, closing a stake of 84,760 shares — an estimated $822K sold.

Fidelity Investments first reported a position in TRIL in Q2 2015 and held it in 6 quarters. The position peaked at $1.86M in Q1 2021. 181 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

  • Fidelity Investments reported no remaining Trillium Therapeutics Inc. position as of Q3 2021 after selling out during the quarter.
  • Fidelity Investments sold 84,760 Trillium Therapeutics Inc. shares in Q3 2021, an estimated $822K.
  • Fidelity Investments first reported a position in Trillium Therapeutics Inc. in Q2 2015 and held it in 6 quarters.
  • Fidelity Investments's Trillium Therapeutics Inc. position peaked at $1.86M in Q1 2021.
  • 181 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on Fidelity Investments's 13F filing for Q3 2021, filed 15 Nov 2021.